Literature DB >> 8148464

Pathogenesis and potential strategies for prevention and treatment of septic shock: an update.

M P Glauser1, D Heumann, J D Baumgartner, J Cohen.   

Abstract

Septic shock is mediated by complex interactions of cells, cytokines, and humoral pathways. Clinical therapeutic strategies aimed at inhibiting selected pathways have been efficacious in subsets of patients. Experimental studies focusing on the activities of single cytokines have contributed to the understanding of the complex pathophysiology of septic shock. More precise delineation of the roles of each mechanism contributing to pathogenesis will permit the identification of subsets of patients who might benefit from particular therapeutic strategies and will guide the development of additional approaches to prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8148464     DOI: 10.1093/clinids/18.supplement_2.s205

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  Characterization of a monoclonal antibody that binds to an epitope on soluble bacterial peptidoglycan fragments.

Authors:  G J Merkel; B A Scofield
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Authors:  T Kawata; J R Bristol; D P Rossignol; J R Rose; S Kobayashi; H Yokohama; A Ishibashi; W J Christ; K Katayama; I Yamatsu; Y Kishi
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

3.  Interaction of NK lysin, a peptide produced by cytolytic lymphocytes, with endotoxin.

Authors:  M Andersson; R Girard; P Cazenave
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

4.  Comparison of inflammation, organ damage, and oxidant stress induced by Salmonella enterica serovar Muenchen flagellin and serovar Enteritidis lipopolysaccharide.

Authors:  Lucas Liaudet; Kanneganti G K Murthy; Jon G Mabley; Pál Pacher; Francisco G Soriano; Andrew L Salzman; Csaba Szabó
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

Review 5.  Antiendotoxin monoclonal antibodies. What future now?

Authors:  G M Susla; R B Dew
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

Review 6.  Treatment of sepsis: past and future avenues.

Authors:  J D Baumgartner; T Calandra
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

7.  Protective effect of pentoxifylline plus thalidomide against septic shock in mice.

Authors:  O Arrieta; A Ortiz-Reyes; D Rembao; M Calvillo; E Rivera; J Sotelo
Journal:  Int J Exp Pathol       Date:  1999-02       Impact factor: 1.925

8.  p-Cymene modulates in vitro and in vivo cytokine production by inhibiting MAPK and NF-κB activation.

Authors:  Weiting Zhong; Gefu Chi; Lanxiang Jiang; Lanan Wassy Soromou; Na Chen; Meixia Huo; Weixiao Guo; Xuming Deng; Haihua Feng
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

9.  Mechanisms involved in the pathogenesis of sepsis are not necessarily reflected by in vitro cell activation studies.

Authors:  C R Amura; R Silverstein; D C Morrison
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

10.  Regulation of bovine acute phase responses by recombinant interleukin-1 beta.

Authors:  D L Godson; M E Baca-Estrada; A G Van Kessel; H P Hughes; M A Morsy; J Van Donkersgoed; R J Harland; D E Shuster; M J Daley; L A Babiuk
Journal:  Can J Vet Res       Date:  1995-10       Impact factor: 1.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.